Callum Sloss

VP of Translational Sciences @ Viridian Therapeutics, Inc.

About

An experienced and dynamic senior Translational Science Leader specializing in oncology, with comprehensive expertise in patient selection strategies, companion diagnostics, staff coaching and mentoring, drug development, clinical and regulatory documentation, and research management. 20 years of experience in oncology therapeutics and 13-plus years of experience in oncology, biomarker, diagnostics, and drug development roles in the biotech sector. Builds and leads scientific teams while managing external vendors to deliver on complex scientific, biomarker, and diagnostic goals within tight timelines. Focused on improving cancer patient outcomes through the implementation of biomarker-driven clinical studies. Core Competencies: ★ Companion Diagnostics | Translational Medicine | Patient Selection ★ Oncology | Drug Development | Clinical Trials | Sample Analysis ★ Assays Development | Program Management | Vendor / Stakeholder Relations

Country

United States

City

Greater Boston

Industry

Biotechnology

Skill

Translational Medicine, Companion Diagnostics (CDx), Oncology, Drug Development, Cancer Research, Clinical Trials, Regulatory Submissions, Biomarkers, Drug Discovery, Biotechnology, Biochemistry, Laboratory Skills, Teaching, Good Clinical Practice (GCP), Translational Research, Molecular Biology, In Vitro, In Vivo, Cell, Cell Biology

Experience

VP of Translational Sciences

Viridian Therapeutics, Inc.

2025-1 - Present · 1 yr 9 mos

Waltham, Massachusetts, United States

Executive Director Translational Sciences (ImmunoGen)

AbbVie

2024 - 2024

Joined AbbVie as part of their February 2024 acquisition of ImmunoGen. Continued in my Executive Director role leading my team to execute on the Translational Science and CDx deliverables for the ELAHERE, IMGN151 and PVEK programs as well as working with AbbVie leadership to integrate ImmunoGen programs and functions into their organization.

Executive Director, Head of Translational Sciences

ImmunoGen, Inc.

2022 - 2024 · 2 yrs

Led the Translational Sciences group (Translational Medicine, Clinical Pharmacology and Toxicology) in support of three clinical stage solid and hematologic oncology programs. Companion Diagnostic lead responsible for overseeing data generation activities required to support the US commercialization, medical affairs activities and EU submissions for the FOLR1 CDx.

Senior Director, Head of Translational Sciences

ImmunoGen, Inc.

2019 - 2022 · 3 yrs

Waltham, Massachusetts, United States

Accountable for rebuilding and restaffing translational sciences team into an outsourced (no internal labs) model after corporate restructuring. Companion Diagnostics lead responsible for development of the FOLR1 CDx required for patient enrollment and commercialization of ELAHERE.

Director, Head of Translational Medicine

ImmunoGen, Inc.

2017 - 2019 · 2 yrs

Waltham, MA

Functional area group leader responsible for all translational medicine deliverables to support global clinical and preclinical development of multiple oncology therapeutics in both solid and hematological malignancies

Associate Director, Translational Medicine

ImmunoGen, Inc.

2016 - 2017 · 1 yr

Waltham, Massachusetts

Biomarker lead for leukemia and lymphoma clinical programs. Overseeing program-specific lab studies as well as pharmacodynamic & biomarker assay development, implementation, execution, and clinical sample analysis

Senior Scientist- Biomarker Lead

ImmunoGen, Inc.

2015 - 2016 · 1 yr

Waltham, Massachusetts

Principal Scientist

Merrimack

2015 - 2015

Cambridge, MA, USA

Responsible for leading and translating pre-clinical research hypotheses and biomarker discovery efforts into clinically tractable biomarker assays for use in retrospective and prospectively stratified/selected oncology clinical trials.